- Maiva Pharma has inaugurated a new manufacturing facility in Shoolagiri, Tamil Nadu, to expand its sterile injectables development and manufacturing capabilities.
- The 22-acre site currently includes three production lines under Phase I and is planned to house six manufacturing lines upon full development.
Maiva Pharma has inaugurated a new manufacturing facility in Shoolagiri, Tamil Nadu, as part of its expansion strategy. The company, which operates as a CMO and CDMO focused on sterile injectables, said the facility will support the development and manufacturing of both generic and complex sterile injectable products for pharmaceutical and biotechnology companies.
The facility is located on a 22-acre site and has been designed with advanced manufacturing technologies, flexible production infrastructure, and quality systems intended to meet global market requirements. According to the company, the site will eventually accommodate six manufacturing lines capable of producing sterile injectable dosage forms, including vials, pre-filled syringes, cartridges, suspension products, and lyophilized formulations.
As part of the Phase I expansion, Maiva Pharma has commissioned three production lines. These include a high-speed vial filling line, an integrated pre-filled syringe and cartridge line, and a lyophilization line. The facility also contains Quality Control chemical laboratories and microbiology laboratories to support in-house analytical testing and quality assurance activities.
The new site expands the company’s contract manufacturing capabilities in sterile injectables and broadens its production infrastructure for multiple delivery formats. The facility is intended to strengthen Maiva Pharma’s ability to serve pharmaceutical and biotechnology customers in global markets.
“The inauguration of our Shoolagiri facility represents a major step in Maiva Pharma’s journey to become a globally preferred partner in sterile injectables manufacturing. The combination of manufacturing technologies, additional capacity, and expanded delivery system capabilities would help the company support customer requirements and increase access to injectable therapies worldwide.”
Dr. Bhaskar Krishna, Managing Director and CEO of Maiva Pharma
